Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25809439 | 0.87 | TAAR1 (0.51) | TAAR1ADRA1AHTR2A | |
| SCHEMBL27758116 | 0.83 | SLC6A4 (0.47) | TAAR1ADRA1AHTR2A | |
| SCHEMBL931667 | 0.81 | SLC6A4 (0.50) | TAAR1HTR2A | |
| SCHEMBL1714771 | 0.80 | IDO1 (0.60) | HTR2A | |
| SCHEMBL15174546 | 0.80 | TSHR (0.49) | HTR2A | |
| SCHEMBL7666659 | 0.79 | SLC6A4 (0.49) | HTR2A | |
| SCHEMBL17224522 | 0.79 | SLC6A4 (0.52) | HTR2A | |
| SCHEMBL21891006 | 0.79 | SLC6A4 (0.49) | HTR2A | |
| SCHEMBL27758118 | 0.79 | SLC6A4 (0.49) | HTR2A | |
| SCHEMBL7363416 | 0.79 | SLC6A4 (0.49) | HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390357-A2 | ANTI-THROMBOTIC COMPOUNDS, PRODUCTION AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2004-02-25 | — | — | EP | disclosed |
| US-20020151534-A1 | Antithrombotic compounds | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-10-17 | — | — | US | disclosed |
| WO-2002062778-A2 | ANTI-THROMBOTIC COMPOUNDS, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151534-A1 | Antithrombotic compounds | SERPINC1, PF4, F2 | TAAR1 2472/4885ADRA1A 1117/4885HTR2A 659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.